QDIS Blog

Well, Anormed is back in the news and the suitor this time is Millennium.

AnorMED Press Release: September 26, 2006:

Seems they didn’t like the Genzyme offer but now have agreed to be acquired by Millennium for $12 per share or a 40% premium over what Genzyme was offering. It is also a 21% premium over the Anormed’s closing price on Sept 25.

This looks like a better option for Anormed shareholders but may be a little on the expensive side. In light of full disclosure, I do own a few shares of Millennium and think they may be paying a little too much for the acquisition.

I find it head spinning with the number of M&A activities in the past few months and unless something changes, I don’t see that changing through the rest of this year, especially in Europe.

For more, here’s the news results from Yahoo and Google.

• Yahoo! News Search Results for anormed millennium
• anormed millennium - Google News

Technorati Tags: Anormed, pharma M&A, pharmaceutical deals, Millenium

Email Ed Vawter

Bookmark it with: | del.icio.us | Digg it | Furl | Simpy | Spurl | My Yahoo! |

Consolidation seems to be all the rage in the pharmaceutical industry recently. I’ve posted about others but here is the latest.

Schwarz Joins Pharma Consolidation Trend - Forbes.com:

Schwarz Pharma will be purchased by UCB of Belgium for 4.4 billiob euros ($5.64 billion US dollars).

I think you will consider to see M&A activity especially in Europe through the ned of the year.
Technorati Tags: pharma M&A, pharmaceutical deals, Schwarz Pharma, UCB

Email Ed Vawter

Bookmark it with: | del.icio.us | Digg it | Furl | Simpy | Spurl | My Yahoo! |